Un estudio para investigar la seguridad, la tolerabilidad, la inmunogenicidad y la farmacodinámica de VXX-401 en comparación con un placebo en participantes adultos
Un estudio de fase 1, primero en humanos, aleatorizado, doble ciego, controlado con placebo, de aumento de dosis para evaluar la seguridad, la tolerabilidad, la inmunogenicidad y la farmacodinámica de VXX-401 en adultos sanos
This first-in-human (FIH) study of VXX-401, an anti-PCSK9 peptide-based immunotherapeutic candidate, is designed to assess the safety, tolerability, immunogenicity, and pharmacodynamics (PD) of VXX-401 and to determine an optimal dose regimen for LDL-C lowering in subsequent clinical trials.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is multisite, multidose regimen, phase 1, first-in-human study of VXX-401, a synthetic peptide-based active immunotherapy candidate for preventing and treating hypercholesterolemia. The study will include Screening, Treatment, and Follow-up Periods. This study will enroll participants who are naïve to statin use. Each cohort from A to D is planned to randomize approximately 12 participants to receive doses of VXX-401 or placebo in a 3:1 ratio. Cohorts E and F will dose approximately 8 participants in each cohort to receive doses of VXX-401. No participants will be administered placebo in Cohorts E and F. It is planned to test up to 6 dose regimens of VXX-401, administered by IM injection into the deltoid muscle (and additionally in the thigh for the first dose in Cohorts E-F.). All eligible participants will receive a priming regimen at Week 0 (Baseline, Day 1), Week 4, and Week 12, in Cohorts A, C, E and F, and additionally at Week 8 in Cohorts B and D. The last dose administration will be at Week 12.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New South Wales
-
Brookvale, New South Wales, Australia
- Northern Beaches Clinical Research
-
Miranda, New South Wales, Australia
- Sutherland Shire Clinical Research
-
Sydney, New South Wales, Australia
- Emeritus Research
-
-
Queensland
-
Morayfield, Queensland, Australia
- University of the Sunshine Coast (USC)
-
-
Victoria
-
Melbourne, Victoria, Australia
- Emeritus Research
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female participants aged 18 to 75 years old, inclusive, at time of informed consent.
- LDL-C level = 2.59 mmol/L - 4.89mmol/L
- Body mass index between 18 and 35 kg/m2, inclusive at Screening, and with a minimum weight of 50 kg.
- Male participants and their partners of childbearing potential must commit to the use of highly effective contraceptives for the study duration and for at least 12 weeks after the last dose. Men must refrain from donating sperm during this same period.
- Female participants must be of nonchildbearing potential, or, for women of childbearing potential, must be willing to practice at least one form of highly effective contraception throughout the duration of the study and for at least 24 weeks following the last dose. Female participants must refrain from donating reproductive tissue during this same period.
Exclusion Criteria:
- Subjects considered high risk or very high risk for ASCVD and requiring immediate treatment with LLT according to the clinical judgement of the investigator.
- History of confirmed anergy (i.e., not able to mount an immunological response) or history of immunization failure in the 5 years prior to the Screening Visit.
- Presence of fever >38°C or other signs or symptoms of acute disease within 1 week before the Screening and/or Visit 1; Screening and/or Visit 1 may be rescheduled at the discretion of the Investigator but must occur within the 4-week window.
- Known disturbance of coagulation or medication (see prohibited medications criterion below); bleeding disorder (e.g., factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.
- Triglycerides > 5.65 mmol/L
- Has a history of clinically significant medical disorder or psychiatric conditions, which in the opinion of the investigator may compromise the participant's safety and ability to comply with study procedures or abide by study restrictions.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: VXX-401 Cohort A
VXX-401 100mcg administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12 |
A synthetic PCSK9 peptide-based immunotherapy |
|
Experimental: VXX-401 Cohort B
VXX-401 100mcg administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12 |
A synthetic PCSK9 peptide-based immunotherapy |
|
Experimental: VXX-401 Cohort C
VXX-401 300mcg administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12 |
A synthetic PCSK9 peptide-based immunotherapy |
|
Experimental: VXX-401 Cohort D
VXX-401 300mcg administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12 |
A synthetic PCSK9 peptide-based immunotherapy |
|
Comparador de placebos: Placebo Cohort A and C
Placebo administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12 |
Normal saline |
|
Comparador de placebos: Placebo Cohort B and D
Placebo administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12 |
Normal saline |
|
Experimental: VXX-401 Cohort E
VXX-401 900mcg administered by intramuscular (IM) injection at Week 0. VXX-401 100 mcg administered by intramuscular (IM) injection at Week 4 and Week 12. |
A synthetic PCSK9 peptide-based immunotherapy |
|
Experimental: VXX-401 Cohort F
VXX-401 900mcg administered by intramuscular (IM) injection at Week 0. VXX-401 300 mcg administered by intramuscular (IM) injection at Week 4 and Week 12. |
A synthetic PCSK9 peptide-based immunotherapy |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Frequency of adverse events
Periodo de tiempo: 30 weeks
|
Safety and tolerability: rates of adverse events (AEs), medically attended adverse events (MAAEs), local (injection site) and systemic (generalized) reactions (i.e., reactogenicity), clinical laboratory assessments (e.g., chemistry, hematology, urinalysis, lipid profile), serum cytokine release, vital signs, physical examinations, and electrocardiograms (ECGs) through the end of the study. |
30 weeks
|
|
Immunogenicity
Periodo de tiempo: Baseline to Week 16, 20, 24, and 30
|
Immunogenicity will be measured by serum anti-PCSK9 antibody titers |
Baseline to Week 16, 20, 24, and 30
|
|
Immunogenicity
Periodo de tiempo: Baseline to Week 16, 20, 24, and 30
|
Seroconversion two-fold and four-fold from baseline |
Baseline to Week 16, 20, 24, and 30
|
|
Determine optimal VXX-401 dose regimen
Periodo de tiempo: Baseline to Week 16, 20, 24, and 30
|
Measured by serum anti-PCSK9 antibody titers |
Baseline to Week 16, 20, 24, and 30
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Evaluation of low-density lipoprotein-cholesterol (LDL-C) reduction
Periodo de tiempo: Baseline to Week 16, 20, 24, and 30
|
Percent change from baseline in serum LDL-C concentration |
Baseline to Week 16, 20, 24, and 30
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Sasha Rumyantsev, Vaxxinity, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- VXX-401-101
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .